Scope Fluidics patents the key solution of the PCR|ONE system in the European Patent Office

02-07-2019

grafikaCuriosity Diagnostics – a company that belongs to the Scope Fluidics S.A. Capital Group – has announced that it has obtained a conditional decision from the European Patent Office on granting the patent for the patent application titled „Device for simultaneous and uniform thermal cycling of samples and uses thereof”. It is the key technology for the functioning of the PCR|ONE system and for the performance parameters which give it a market advantage. Formerly, the company patented this technology in the US market. At the same time, it is continuing its work on gaining protection in the Chinese market.

The PCR|ONE system has a great market advantage, and that is why, as we announced before, we are expanding the patent protection of our key inventions onto further markets. This technology, already protected in the US market and now expanded into European ones, enables us to run the ultrafast polymerase chain reaction on many samples at the same time. It is one of the key solutions guaranteeing a market advantage, explains Marcin Izydorzak, co-owner, key shareholder and CEO of Scope Fluidics S.A. We are working on expanding the protection to the Chinese market, too, he adds.

In order for the patent to be granted, the wording of the application as proposed by the Office must be approved. Moreover, the required translations and fees are required.

At the end of June, Curiosity Diagnostics completed on time the fourth stage of research and development works on the PCR|ONE system, and by that became prepared to start the second round of preregistration tests. They will be carried out by an independent partner – ALAB Laboratoria.

The first round of testing in ALAB Labs was completed in the second half of 2018. At that time, the PCR|ONE system managed to obtain high sensitivity and specificity parameters compared to a competitive product, and it proved that it is unbeatable in terms of the speed of analysis of genetic material. Scope Fluidics used the conclusions and recommendations gathered in the testing process to further optimize the functionality of the system and the production cost of disposable cartridges, company. The second round of testing will be conducted in July 2019 and will end in Q1 2020 at the latest.